A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS
- Registry ID
- AS0008
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- UCB INC
- Start date
- 2016-11-23
- Last update
- 2016-11-23
Conditions
- ACTIVE ANKYLOSING SPONDYLITIS
View on source registry